
Second Extension of the Timeline for Including COVID-19 Products in the wambo.org Pilot

GF/B44/ER17

Electronic Report to the Board

1 April 2021

Board Decision

Purpose of the paper: This paper presents the Strategy Committee's recommendation to the Board for a second extension to the timeline of the Board-approved mandate (established in GF/B43/EDP07 and extended through GF/B43/EDP17) to include COVID-19 products as part of the wambo.org pilot for non-grant financed orders until no later than November 2022 or until the Board approves a future strategy for wambo.org if earlier.

Decision

Decision Point: GF/B44/EDP24: Second Extension of the Timeline for Including COVID-19 Products in the wambo.org Pilot

The Board:

- 1. Recalls GF/B43/EDP07 where it decided to extend the scope of the wambo.org pilot to allow for eligible buyers, as defined in GF/B42/DP05, to purchase all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients and specified that such non-Global Fund financed transactions for COVID-19 products will be issued as purchase orders by wambo.org within the period ending 31 December 2020, unless extended by the Board following recommendation by the Strategy Committee;***
- 2. Recalls GF/B43/EDP17 where the Board approved the change in the end date of such period to 31 May 2021; and***
- 3. Based on the recommendation of the Strategy Committee, approves the change in the end date of such period through which non-Global Fund financed transactions for COVID-19 products may be issued as purchase orders by wambo.org until November 2022 or until the Board approves a future strategy for wambo.org if earlier and confirms that all other conditions and flexibilities set forth in GF/B43/EDP07 shall continue to apply.***

Budgetary implications (included in, or additional to, OPEX budget)

The cost of additional licenses associated with the use of wambo.org will be absorbed within the Secretariat's existing license packages, which currently include some unused licenses. If further licenses are needed, costs and options to cover these costs will be evaluated by the Secretariat.

Costs relating to the expansion of the product catalogue to include COVID-19 products, which are already being incurred as a result of the creation of C19RM under GF/B42/EDP11, will be managed within the existing budget and will be incurred independently of this decision.

There are no other anticipated budgetary implications at this time, as new buyer onboardings and transactions will be managed by existing staff.

A summary of relevant past decisions providing context to the proposed Electronic Decision Point can be found in Annex 1.

Executive Summary

Context

- In recognition of the impact of COVID-19 on implementing countries' ability to fight HIV, tuberculosis and malaria, the Global Fund has taken swift and decisive action by (i) establishing grant flexibilities, (ii) establishing and extending the COVID-19 Response Mechanism (C19RM) (GF/B42/EDP11 and GF/B44/EDP12) and (iii) allowing for the wambo.org pilot for non-grant financed orders to include COVID-19 products (GF/B43/EDP07 and GF/B43/EDP17). To date US \$980 million¹ has been approved to support countries' COVID-19 responses through the first two actions. The Secretariat has deployed its sourcing capabilities and engaged with partners to facilitate the procurement of COVID-19 products with Global Fund funding.
- There remains a need to continue to provide mechanisms to support countries with their COVID-19 responses. The use of wambo.org to purchase COVID-19 products with non-Global Fund sources of funding continues to remain a good option for governments and non-governmental development organizations in Global Fund-eligible and transitioned countries to procure COVID-19 products offered to Global Fund Principal Recipients through the wambo.org platform (subject to agreement between the Global Fund and the supplier and subject to available supply). The timeline of the mandate granted under GF/B43/EDP07 and extended through GF/B43/EDP17 currently requires purchase orders for these non-grant transactions for COVID-19 products to be issued by 31 May 2021. If no action is taken to extend this timeframe, this procurement channel option for countries to access COVID-19 products with non-grant funds will cease on that date.
- Given the current trajectory of the pandemic, the Strategy Committee recommends that the mandate to include COVID-19 products in the wambo.org pilot for non-grant financed orders be extended until the end of the overall wambo.org pilot, i.e., until no later than November 2022 or until the Board approves a future strategy for wambo.org if earlier.² On a bi-annual basis, the Strategy Committee will continue to receive updates on the pilot, with COVID-19 product transactions disaggregated from reporting on other pilot transactions. The Strategy Committee may recommend that the Board consider a decision to halt processing of new transactions for COVID-19 products at any time prior to the end of November 2022 based on the bi-annual reporting updates or other information, including the independent evaluation commissioned by the TERG of the wambo.org pilot.
- While to date there has only been one non-grant financed order placed for COVID-19 products through wambo.org, discussions with other country organizations are ongoing. The Strategy Committee considers that continuing to include COVID-19 products in the pilot is beneficial and there is little incremental cost to extending the timeline to no later than November 2022. Non-grant financed orders for COVID-19 products may further increase as supply stabilizes, new products including treatments enter the market

¹ [COVID-19 Situation Report #38](#)

² The current wambo.org pilot for non-grant financed orders will end no later than on November 2022.

(particularly those where the Global Fund may have increased access to supply and/or favorable terms and conditions), and as countries become more aware of the possibility to procure COVID-19 products through wambo.org using their own funds and/or the Secretariat further explores partnership activities.

Input Sought

As recommended by the Strategy Committee in GF/SC15/DP01, the Board is requested to approve the Electronic Decision Point: GF/B44/EDP24: Second Extension of the Timeline for Including COVID-19 Products in the wambo.org Pilot.

Questions this paper addresses

- A. What do we propose to do and why?
- B. What options were considered?

Conclusions

- A. The Strategy Committee recommends that the Board extend the timeline for accessing COVID-19 products through the wambo.org pilot until no later than November 2022 or until the Board approves a future strategy for wambo.org if earlier.
- B. The Strategy Committee considered several options, including allowing the mandate to include COVID-19 products in the pilot expire on 31 May 2021, as well as a one-year extension to 31 May 2022. However, in light of the disaggregated bi-annual reporting to the Strategy Committee, the minimal incremental cost to extending the timeline of the GF/B43/EDP07 and GF/B43/EDP17 mandate, and the potential value to countries and partners to have access to another procurement option in the future for COVID-19 products, particularly as more products for testing and treatment become available, the Strategy Committee recommends that the Board extend the time period during which purchase orders for COVID-19 products can be issued under the wambo.org pilot until no later than November 2022, in line with the wambo.org pilot timeline, or until the Board approves a future strategy for wambo.org if earlier.

Input Received

- This decision point builds on discussions held by the Strategy Committee at its 15th meeting.
- The decision point also builds on discussions held with constituencies in advance of the Board decision GF/B43/EDP07: Extending the wambo.org pilot to include COVID-19 products and Board decision GF/B43/EDP17 which extended the timeline for inclusion of these products.

What is the need or opportunity?

1. In July 2020, the Board approved an expansion of the wambo.org pilot for non-grant-financed orders to include COVID-19 products available through wambo.org to Global Fund Principal Recipients with an initial timeframe of 31 December 2020. In October 2020, the Board agreed to extend the timeframe for the inclusion of COVID-19 products through 31 May 2021.
2. As of 31 March 2021, there has been one non-grant-financed requisition submitted for COVID-19 products as part of the pilot, which permits the country to access their WHO-led allocation of automated PCR SARS-CoV-2 tests from Cepheid with domestic funding through the wambo.org platform. Their decision to do so was informed by their familiarity with the platform through their participation in the Global Fund's Pooled Procurement Mechanism. Discussions with other country organizations are ongoing. Explanations for the lack of additional COVID-19 product transactions at this time include supply constraints on certain key products; the existence of other procurement channels offering many of the same products; and/or the lack of partnerships with large donors that have materialized thus far.
3. The Strategy Committee considers that there is value in extending the timeline of the inclusion of COVID-19 products in the wambo.org pilot. The possible benefits to countries and partners outweigh the limited potential cost. As additional products become available, particularly those where the Global Fund has strategic access to supply and/or terms and conditions, the value of non-grant buyers accessing these items through wambo.org may increase. Moreover, partnerships are still being explored and may become more relevant in the future, at which point it would be helpful for the Secretariat to have the Board mandate to offer them the option of procuring COVID-19 products through the wambo.org pilot.

What is proposed and why?

What is the proposal?

4. The Strategy Committee recommends that the Board approve a second extension of the timeline until no later than November 2022, or until the Board approves a future strategy for wambo.org if earlier, to continue to make available COVID-19 products to buyers using non-Global Fund funding through the pilot. This extension would allow for purchase orders for COVID-19 products to be issued through wambo.org until no later than November 2022. The rationale for offering the option to procure COVID-19 products through the wambo.org pilot is described in GF/B43/EDP07 and remains unchanged.

Why is this the recommended option?

5. Although there has only been one order as of 31 March 2021, the Strategy Committee believes that from a cost-benefit perspective, there is value in extending the timeline of the inclusion of COVID-19 products in wambo.org. Benefits include the availability of an additional tool for countries to access quality COVID-19 products as part of the global response to COVID-19 and the significant benefits that beneficiaries in Global Fund-eligible and transitioned countries could potentially gain from improved access to pooled procurement volumes of these products.
 - i. *Cost to the Secretariat:* Beyond the process of requesting an extension from the Board, there is little incremental level of effort needed to continue to offer COVID-19 products for non-grant-financed orders through the pilot. If countries or partners wish to make use of this option, the incremental needs of additional user licenses are expected to be covered at no extra cost through the Secretariat's existing license agreement, and staff time spent managing onboarding, support and transactions is expected to represent a marginal increase over current workload.

- ii. *Potential value to Global Fund-eligible and transitioned countries and partners:* As new products enter the market (e.g., new diagnostic tests and treatments), as the Secretariat furthers its strategic sourcing activities related to COVID-19 products (i.e., expanding procurement sources, as it has now done for PPE), as supply of key products potentially increases and/or Global Fund funding for COVID-19-related procurement decreases, and as partnerships with donors are potentially established, the benefits of procuring COVID-19 products using non-Global Fund funding through wambo.org may increase substantially. Providing another option for countries and partners to procure quality products via a trusted and transparent international procurement channel can increase the Global Fund's impact in the global response to COVID-19 at little additional effort and cost.

What are the risks and proposed mitigations?

6. In consideration of the trajectory of the pandemic, the Strategy Committee considers that restricting access to orders of COVID-19 products available on the platform to only Global Fund financed orders may pose a greater risk to protecting Global Fund investments to fight the three diseases than permitting non-grant financed orders of COVID-19 products within the scope of the overall wambo.org pilot. The Secretariat has not identified any additional risks from extending the timeline of the decision to include COVID-19 products in the wambo.org pilot, noting that the risks and mitigation actions described in GF/B43/EPD07 continue to apply. The Secretariat will continue to report on COVID-19 transactions under the pilot bi-annually to the Strategy Committee, as described in GF/B43/EDP07 and as approved by the Strategy Committee in GF/SC14/12, for the duration of the extended timeline. Based on these bi-annual updates, the Strategy Committee may recommend a decision to the Board at any time to halt the COVID-19 product component of the pilot. The evaluation of the pilot will include all non-grant-financed orders, extracting lessons from the pilot for the products available via the wambo.org platform, both non-COVID-19 products and COVID-19 products, to inform a future strategy for wambo.org.
7. The statutory audit of 2020 Annual Financial Statements identified gaps and associated risks on procurement transactions of grant-funded orders through the wambo.org platform which did not result in a control deficiency as the Secretariat had manual compensating and detective controls in place [GF/AFC15/02B]. Remedial system enhancements have already been implemented, and in addition, a Supply Operations-led end-to-end process review and related COSO work will enable the embedding of these controls as a part of continuous improvement. Though not directly linked to the pilot, these improvements are expected to benefit pilot transactions as well.

What options were considered?

What are the options?

8. The Strategy Committee considered a number of options, in terms of additional cost and level of effort, versus the potential value to countries and partners having another trusted international procurement option for COVID-19 products, particularly as the Secretariat considers and potentially expands its future COVID-19 sourcing strategy for grant-funded procurements. These options include:
 - i. Option 1 (the recommended option): extending the timeline until no later than November 2022 or until the Board approves a future strategy for wambo.org.
 - ii. Option 2: extending the timeline by one year to 31 May 2022.

- iii. Option 3: allowing the inclusion of COVID-19 products within the wambo.org pilot to expire, and thereby eliminating the possibility for buyers using non-grant sources of funding to procure COVID-19 products through wambo.org beyond 31 May 2021.

Given the above, what are the positives and negatives of each option?

9. Option 1: extending the timeline of availability of COVID-19 products until no later than November 2022 or until the Board approves a future strategy for wambo.org.
 - i. *Positives:* For little additional cost or effort to the Secretariat, countries and partners have access to another international procurement option for executing their COVID-19 response. As more products enter the market and as the Global Fund's sourcing strategy for COVID-19 products for grant-funded procurements potentially evolves, this option may become increasingly attractive and relevant for certain countries or partners. As approved in GF/SC14/12, the Strategy Committee will receive bi-annual updates on the pilot, with transactions for COVID-19 products disaggregated. Transactions for COVID-19 products will be included in the evaluation of the pilot which will help inform the development of a future strategy for wambo.org. Based on the bi-annual progress updates, the Strategy Committee may recommend at any time that the Board consider a decision to halt implementation of the COVID-19 component of the pilot.
 - ii. *Negatives:* There is some incremental cost to extending the timeline allowing COVID-19 products to be procured through the wambo.org pilot, such as the effort involved in onboarding and supporting potential new buyers and in managing their COVID-19 transactions. In addition, new users will require licenses. However, the Secretariat currently has unused licenses under its arrangement with the wambo.org platform service provider, which cover the expected low to moderate uptake of the platform by new buyers under this scope.
10. Option 2: extending the timeline of availability of COVID-19 products through the pilot only by one year to 31 May 2022.
 - i. *Positives:* The positives are as described for Option 1 for the period ending 31 May 2022.
 - ii. *Negatives:* In addition to each of the negatives described above for Option 1, under Option 2, there is an inefficiency linked to the misalignment in timing for the COVID-19 component with the evaluation and future strategy for the pilot more broadly. In the first half of 2022, the Strategy Committee would in any case receive an update on the pilot, with COVID-19 transactions disaggregated, based upon which a decision could be taken by the Board to halt implementation of the COVID-19 component of the pilot in the event of any red flags. However, in the event that there are no red flags and it should be determined to be desirable for additional COVID-19 transactions to progress beyond 31 May 2022 alongside the pilot for non-COVID-19 products which will run until no later than November 2022, dedicated time of the Secretariat, Strategy Committee and Board would be required for a decision on a 6-month extension of the COVID-19 component of the pilot. As the Strategy Committee could recommend halting implementation of the COVID-19 component of the pilot based on the update to be reported in the first half of 2022, Option 2 appears to be a less efficient use of time, as it would require that a decision be taken before 31 May 2022, even in the event that no red flags were identified for the COVID-19 component of the pilot, in addition to a decision to be taken regarding the pilot overall no later than November 2022.
11. Option 3: allowing the inclusion of COVID-19 products in the wambo.org to expire and no longer offering buyers the possibility to procure COVID-19 products through the wambo.org pilot beyond 31 May 2021.

- i. *Positives:* This option entails a slightly reduced workload for the Secretariat from foregoing any incremental onboarding, support or transaction management efforts stemming from orders for COVID-19 products placed through the pilot. There would also be potential financial savings resulting from not using additional licenses if uptake were to increase, unexpectedly, beyond the currently available, unused licenses.
- ii. *Negatives:* Any countries or partners wanting to access COVID-19 products through the pilot would be unable to do so after 31 May 2021. Although there are other international procurement channels for products currently offered through the pilot, this may not be the case in the future, and buyers may have specific reasons for choosing wambo.org in lieu of other procurement channels, such as familiarity with the platform, use of the platform for procurements for HIV, tuberculosis and malaria, preference for its transparency and tracking features, etc. Letting this inclusion expire simply reduces the number of procurement options available to countries and partners when executing their COVID-19 response.

What needs to be done next to progress?

What is required to progress the proposal?

12. In line with GF/B43/EDP07, the Strategy Committee recommends that the Board approve a second extension to the existing mandate to include COVID-19 products under the wambo.org pilot until no later than November 2022.

What will the Board/Committee have to do next?

13. Pending a positive Board decision, the Strategy Committee will continue to receive bi-annual updates on the progress of the wambo.org pilot overall, including COVID-19 transactions.
14. Findings from the TERG review of the wambo.org pilot, including COVID-19 transactions, will be reported to the Strategy Committee.

What would be the impact of delaying or rejecting the decision to progress?

15. Delaying the decision could result in a gap of service to countries or buyers, since the current decision point requires purchase orders to be issued by 31 May 2021. It could discourage some buyers who may be considering using wambo.org for COVID-19 products from registering and placing orders (given the uncertainty of availability beyond 31 May 2021) and/or result in disruptions to ongoing requests that do not yet have an issued purchase order by 31 May 2021. These impacts could create reputational risk for the Global Fund.
16. Rejecting the decision to progress would prevent the Secretariat from engaging with countries and partners who may wish to procure COVID-19 products through wambo.org in the future using non-Global Fund funds and would reduce the international procurement channels available to countries and partners as they plan and execute their COVID-19 responses, as described above.

Recommendation

The Strategy Committee recommends the Decision Point presented on page 2 to the Board.

Annexes

The following items can be found in Annex:

- Annex 1: Relevant Past Decisions
- Annex 2: Links to Relevant Past Documents & Reference Materials

Annex 1 – Relevant Past Decisions

Relevant Past Decision Point	Summary and Impact
<p>GF/SC15/DP01: Second extension of the timeline for including COVID-19 products in the wambo.org pilot (March 2021)</p>	<p>Recalling Board Decision GF/B43/EDP07 and GF/B43/EDP17, the Strategy Committee discussed the proposal by the Secretariat for a second extension to the timeline for including COVID-19 products in the wambo.org pilot to end November 2022. The Strategy Committee recommended the Decision Point presented in GF/SC15/DP01 to the Board for approval. (Further details in GF/SC15/03.)</p>
<p>GF/B43/EDP17: Decision on extending the timeline for including COVID-19 products in the wambo.org pilot (October 2020)</p>	<p>Based on the recommendation of the Strategy Committee (GF/SC14/DP05), the Board approved the extension of the timeline during which non-Global Fund financed transactions for COVID-19 products may be issued as purchase orders to 31 May 2021 and confirmed that all other conditions and flexibilities in GF/B43/EDP07 continue to apply.</p>
<p>GF/SC14/DP05: Extending the timeline for including COVID-19 products in the wambo.org pilot (October 2020)</p>	<p>The Strategy Committee discussed the proposal by the Secretariat to extend the timeline for including COVID-19 products in the wambo.org pilot to 31 May 2021. The Strategy Committee recommended the Decision Point presented in GF/SC14/DP05 to the Board for approval. (Further details in GF/SC14/13.)</p>
<p>GF/SC14/DP04: wambo.org pilot reporting metrics (October 2020)</p>	<p>The Strategy Committee discussed the proposal by the Secretariat for reporting metrics to monitor progress of the wambo.org pilot for non-grant-financed orders until the end of 2022 or until the Board approves a future strategy for wambo.org. The reporting metrics were based on the results of the January 2020 wambo.org multi-stakeholder consultations with constituencies. The Strategy Committee approved the Decision Point presented in GF/SC14/DP04. The Secretariat was requested to engage with the TERG for feedback on the reporting metrics (e.g., to identify any key gaps) and to advance next steps related to the planned independent evaluation of the pilot. (Further details in GF/SC14/12.)</p>
<p>GF/B43/EDP07: Extending the wambo.org pilot to include COVID-19 products (July 2020)</p>	<p>The Board extended the scope of the wambo.org pilot to include the purchase of all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients. The transactions are subject to agreement by the Global Fund and, if applicable, to agreement by the product catalogue owners or manufacturers, they do not count towards the cap of USD 50 million of transactions for the pilot applicable to non-COVID-19 products, and they may be issued as Purchase Orders by 31 December 2020, unless extended by the Board following recommendation by the Strategy Committee.</p> <p>The Board further decided that the transactions for COVID-19 products will be included in the biannual reporting on the Pilot to the Strategy Committee, using metrics for reporting to be agreed by the Strategy Committee in October 2020. However, COVID-19 product transactions will be disaggregated from reporting on other Pilot transactions, so</p>

Relevant Past Decision Point	Summary and Impact
	<p>as to enable integration with overall reporting on the COVID-19 response, and to avoid distorting reporting on the original Pilot.</p>
<p><u>GF/B42/DP05: Evolving the wambo.org pilot for non-Global Fund-financed orders</u> (November 2019)</p>	<p>Based on the recommendation of the Strategy Committee (presented in GF/B42/04- Revision 1) the Board decided that, within defined scope of the wambo.org pilot, wambo.org may be made available for non-Global Fund-financed orders by governments and non-government development organizations in Global Fund-eligible and transitioned countries, for all products, services and functionalities as they become available on wambo.org, up to a cap of USD 50 million of transactions; and instructed the Secretariat to undertake consultations early in 2020, an evaluation of the wambo.org pilot in 2022 and bi-annual reporting on progress of the wambo.org pilot to the Strategy Committee.</p> <p>The Board also delegated to the Strategy Committee the authority to: (i) approve a higher cap for transactions within the scope prior to the consultations in 2020; and (ii) establish the future parameters of the wambo.org pilot within the scope, based on the outcome of the 2020 consultations.</p> <p>The Board further requested the Secretariat to include the results of the 2022 evaluation in the development of a strategy for future advancement of wambo.org to be presented for Board approval at the conclusion of the wambo.org pilot no later than November 2022.</p>
<p><u>GF/SC11/07: Extending access to wambo.org for non-Global Fund-financed orders</u> (October 2019)</p>	<p>The Strategy Committee discussed the proposal by the Secretariat to make wambo.org available for non-grant orders outside of pilot mode. The Strategy Committee requested additional consultations and a formal evaluation of wambo.org prior to exiting the wambo.org pilot.</p> <p>The Strategy Committee unanimously agreed to recommend to the Board for approval making wambo.org available for orders financed with non-grant funds on an evolved pilot basis, whereby governments and non-government development organizations in Global Fund eligible and transitioned countries may have access to wambo.org, to all products, services and functionalities as they become available on wambo.org, subject, if applicable, to agreement by the product catalogue owner, up to a limit of US \$50 million in transaction value. The</p>

Relevant Past Decision Point	Summary and Impact
	<p>Strategy Committee would have delegated authority to adjust the value or the nature of the cap.</p>
<p><u>GF/SC09/DP1: wambo.org: Update on Implementation and Request for Additional Domestic Funding Transactions</u> (March 2019)</p>	<p>The Strategy Committee discussed the implementation of wambo.org for Principal Recipients using wambo.org to procure with grant funds, as well as with domestic funds as part of the pilot approved by the Board under GF/B37/DP09. In accordance with delegated authority under GF/B37/DP09, it decided to approve 50 additional transactions to be conducted on wambo.org with domestic funding, on a pilot basis, within the same scope as approved by the Board under GF/B37/DP09.</p> <p>The Strategy Committee further requested the Secretariat to report back to the Strategy Committee with a final evaluation of the pilot and a strategy for future advancement of wambo.org.</p>
<p><u>GF/B37/DP09: wambo.org: Progress Update and Steps for Advancement</u> (May 2017)</p>	<p>Based on the recommendation of the Strategy Committee, the Board approved the piloting of a limited number of transactions (no more than ten) by current Principal Recipients using domestic funding via wambo.org.</p> <p>The Board also requested the Secretariat to provide draft indicators of success of the pilot, and to report regularly on the operationalization of the pilot, to the Strategy Committee.</p> <p>Lastly, the Board delegated to the Strategy Committee the authority to approve further domestic funding transactions via wambo.org on a pilot basis.</p>
<p><u>GF/SC03/DP02: wambo.org: Progress Update and Steps for Advancement</u> (March 2017)</p>	<p>The Strategy Committee discussed and provided input into the progress of wambo.org to date and the supplemental information addressing questions and concerns raised during the voting process and subsequent consultations after the Board did not adopt the same pilot that is presented in GF/SC03/16. The Strategy Committee recommended the Decision Point presented in GF/SC03/16 to the Board for approval with 9 votes in favor, and 1 abstention.</p>
<p><u>GF/AFC02/DP01 and GF/SC02/DP01: wambo.org: Progress Update and Steps for Advancement</u> (October 2016)</p>	<p>The Audit and Finance Committee and the Strategy Committee jointly discussed and provided input into the progress of wambo.org to date and the steps for advancement as described in GF/AFC02/23a and GF/SC02/06a. The Audit and Finance Committee and the Strategy Committee unanimously recommended the decision point therein to the Board for approval.</p> <p>Following the Audit and Finance Committee and the Strategy Committee discussions, the proposed pilot was submitted to the Board in November 2016 as an electronic decision point. The recommendation received the two-thirds majority required for the decision point to pass in the implementer group. However, it did not receive the same required two-thirds majority in the donor group, where two constituencies voted against the decision point and two abstained. As such, the decision point did not pass at that time.</p>

Relevant Past Decision Point	Summary and Impact
<p><u>GF/B35/DP08: Sustainability, Transition and Co-financing Policy</u> (April 2016)</p>	<p>Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the Sustainability, Transition and Co- Financing Policy, as set forth in Annex 1 to GF/B35/04 - Revision 1.</p>
<p><u>GF/B34/DP08: Approval of the Amended and Restated Market Shaping Strategy</u> (November 2015)</p>	<p>Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approved the Amended and Restated Market Shaping Strategy, as set forth in Annex 1 to GF/B34/17 - Revision 1 (the “Amended and Restated Market Shaping Strategy”). This decision point and the Amended and Restated Market Shaping Strategy supersede Board decision point GF/B23/DP21 and the previous Market Shaping Strategy set forth in Annex 1 to GF/B23/09 – Revision 1. wambo.org was recognized in the Market Shaping Strategy as one way to channel the Market Shaping Strategy while contributing to its objectives.</p>
<p><u>GF/B23/DP21: Global Fund Market Shaping Strategy and Market Shaping Interventions for ARVs</u> (May 2011)</p>	<p>The Board acknowledged the Global Fund’s critical role in shaping markets to maximize global access to health products and further emphasized its desire for the Global Fund to more actively shape markets for health products to optimize price, quality, design and sustainable supply. The Board approved the market-shaping strategy recommended by the Market Dynamics Committee, including a set of specific interventions for anti-retroviral medicines (ARVs). This strategy superseded the Market Shaping Strategy approved in 2007 (GF/B15/DP15).</p>
<p><u>GF/B23/DP09: Plan for Comprehensive Reform: Value for Money</u> (May 2011)</p>	<p>The Board recognized that the Global Fund is well positioned to drive value for money and leverage its role as the primary financier of essential health products to improve quality, price, design, and sustainable supply. The Board asked the Market Dynamics Committee to propose expanded uses of the Global Fund’s market dynamics “toolkit”. Among other directives, it also requested the Secretariat to take all necessary and appropriate measures to fully implement voluntary pooled procurement and aggressively execute the Market Dynamics Committee recommendations.</p>
<p><u>GF/B15/DP15: Market Dynamics and Voluntary Pooled Procurement</u> (April 2007)</p>	<p>The Board adopted the objective and guiding principles for market shaping set out at the 14th Board meeting and amended at this meeting. In addition, the Board decided to pursue voluntary pooled procurement as the first element of its market dynamics strategy. As such, the Board required that the pooled service shall be operated by one or more global or regional procurement agent(s), and that the Secretariat “shall direct the Procurement Agent to seek to award contracts for a given product to several suppliers, where possible and appropriate in view of consideration of market dynamics.” Finally, participants in the pooled service must agree to direct payment to the procurement agent for purchases. It also determined to strengthen the “Price Reporting Mechanism” (now the Price Quality Reporting Mechanism) and enter into contracts to provide procurement capacity-building services to Principal Recipients.</p>

Annex 2 – Relevant Past Documents & Reference Materials

- a) [Second extension of the timeline for including COVID-19 products in the wambo.org pilot](#) GF/SC15/03 (March 2021)
- b) [wambo.org bi-annual reporting on non-grant financed orders](#), GF/SC15/15 (March 2021)
- c) [Update on wambo.org Pilot](#), GF/SC14/11 (October 2020)
- d) [wambo.org Pilot Reporting Metrics](#), GF/SC14/12 (October 2020)
- e) [Extending the Timeline for the Inclusion of COVID-19 Products in the wambo.org Pilot](#), GF/B43/EDP17 (October 2020)
- f) [Extending the Timeline for Inclusion of COVID-19 Products in the wambo.org Pilot](#), GF/SC14/13 (October 2020)
- g) [Extending the wambo.org Pilot to Include COVID-19 Products](#), GF/B43/EDP07 (July 2020)
- h) [Update on wambo.org](#), GF/SC12/06 (March 2020)
- i) [Evolving the wambo.org Pilot for Non-Global Fund-financed Orders – Revision 1](#), GF/B42/04 (November 2019)
- j) [Extending Access to wambo.org for Non-Global Fund-financed Orders](#), GF/SC11/07 (October 2019)
- k) [wambo.org: Update on Implementation and Request for Additional Domestic Funding Transactions](#), GF/SC09/11 (March 2019)
- l) [wambo.org: Progress Update and Steps for Advancement](#), GF/B37/07 – Revision 2 (May 2017)
- m) [wambo.org: Progress Update and Steps for Advancement, GF/B35/ER17](#) (November 2016)